₩ 9370
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
GI Innovation, Inc. specializes in the research and creation of biopharmaceutical products. Its current developmental portfolio features drug candidates G-101, G-102, G-301, and G-108. Founded by Jang Myoung-ho on July 19, 2017, the company's main operations are situated in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only